Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05526989 2025-12-04

Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma

Phase 2 Recruiting

25 enrolled

Genitourinary

Penile Neoplasms

NCT06333314 2025-12-02

Pan-MSI-ACSE

Phase 2 Recruiting

120 enrolled

EndocrineSarcoma

Neoplasm Metastasis, Neoplasms, Sarcoma, Adrenocortical Carcinoma, Carcinoma, Neuroendocrine

NCT06796907 2025-10-14

BEHOLD-2

Phase 1/2 Recruiting

392 enrolled

Tumor-Agnostic

Neoplasms

NCT06256588 2025-09-25

JADE

Phase 3 Recruiting

864 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06023862 2025-06-15

DOVE

Phase 2 Recruiting

198 enrolled

Gynecologic

Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Adenocarcinoma, Clear Cell

NCT05239546 2025-05-25

NAIO

Phase 2 Recruiting

25 enrolled

Gastrointestinal

Colonic Neoplasms

NCT05559879 2025-05-04

Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

Phase 1/2 Recruiting

37 enrolled

Gynecologic

Carcinoma, Uterine Neoplasms, Endometrial Neoplasms

NCT06757244 2025-03-18

DOVIPA

Phase 2 Recruiting

35 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT05784012 2025-03-13

RADIAN

Phase 1/2 Recruiting

34 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Laryngeal Diseases, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06762405 2025-02-18

PREDIR-NEOREC

Phase 3 Recruiting

68 enrolled

GastrointestinalOther solid neoplasm

Rectal Adenocarcinoma with Mismatch-repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H)

NCT06278857 2024-12-03

SATELLITE

Phase 2 Recruiting

10 enrolled

Gynecologic

Turcot syndrome, Endometrial Neoplasms

NCT04817956 2024-02-29

IMPRESS-N

Phase 2 Recruiting

3,000 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT06059495 2024-02-05

DEWI

Phase 2 Recruiting

59 enrolled

Gastrointestinal

Adenocarcinoma - GEJ

NCT04681469 2022-08-04

PRIME

Phase 2 Recruiting

49 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

Clinical Trials

I-SPY

AZUR-4

Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer

Superhero

Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)

Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery

Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine Cervical Carcinoma

A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)

ROCSAN

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma

Pan-MSI-ACSE

BEHOLD-2

JADE

DOVE

NAIO

Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

DOVIPA

RADIAN

PREDIR-NEOREC

SATELLITE

IMPRESS-N

DEWI

PRIME